Donald Trump & John Moolenaar

Donald Trump: President Trump's administration implemented the ban, aligning with his 'America First' policy. The move may bolster his image on national security.

John Moolenaar: Congressman John Moolenaar supported the ban, advocating for legislation to codify it. His support strengthens the policy's political backing.

Donald Trump: Trump's role in brokering the split will be questioned during the hearing.

John Moolenaar: Moolenaar, as committee chairman, announced the hearing but declined to comment on Farrell's testimony.

Donald Trump: Donald Trump's administration is responsible for the blacklisting, which occurred despite recent efforts to stabilize US-China relations, indicating a continued hardline stance on trade and security.

John Moolenaar: John Moolenaar, as chair of the House Select Committee on China, publicly supported the expanded blacklist and urged American businesses to cease dealings with the listed companies.

Donald Trump: His administration oversaw the expansion of the UFLPA Entity List, marking the first additions under his tenure.

John Moolenaar: Congressman who publicly supported the U.S. action, reinforcing the political stance.

Donald Trump: Donald Trump signed the Biosecure Act into law, which restricts federal agencies' business dealings with non-U.S. biotechnology companies, reflecting a broader U.S. policy trend relevant to the current investigations.

John Moolenaar: John Moolenaar, a Republican Representative and chair of the United States — House Select Committee on the Chinese Communist Party, is leading the investigation into Merck & Co. and AbbVie. He is also sponsoring the Biotech Investment National Security Act to further regulate U.S. biotechnology investments in China.